This table contains 36 series, with data for years 1996 - 1998 (not all combinations necessarily have data for all years). This table contains data described by the following dimensions (Not all combinations are available): Geography (4 items: Nova Scotia; Alberta; British Columbia; New Brunswick ...), Sex (3 items: Males; Females; Both sexes ...), Characteristics (3 items: 180-day net survival rate for all stroke; High 95% confidence interval; 180-day net survival rate for all stroke; Low 95% confidence interval; 180-day net survival rate for all stroke ...).

This dataset presents information on age-sex specific occurrence rates of stroke for Alberta, expressed as per 100,000 population.

This dataset presents information on age-standardized incidence rates of stroke for Alberta, AHS continuum zones, former health regions, peer groups, and sub-zones expressed as per 100,000 population.

This table contains 36 series, with data for years 1996 - 1998 (not all combinations necessarily have data for all years). This table contains data described by the following dimensions (Not all combinations are available): Geography (4 items: Nova Scotia; Alberta; British Columbia; New Brunswick ...), Sex (3 items: Males; Females; Both sexes ...), Characteristics (3 items: 180-day net survival rate for all stroke; High 95% confidence interval; 180-day net survival rate for all stroke; Low 95% confidence interval; 180-day net survival rate for all stroke ...).

Objectives: To investigate the hypothesis that strokes occurring in patients with COVID-19 have distinctive features, we investigated stroke risk, clinical phenotypes, and outcomes in this population. Methods: We performed a systematic search resulting in 10 studies reporting stroke frequency among COVID-19 patients, which were pooled with one unpublished series from Canada. We applied random-effects meta-analyses to estimate the proportion of stroke among COVID-19. We performed an additional systematic search for cases series of stroke in COVID-19 patients (n=125) and we pooled these data with 35 unpublished cases from Canada, USA, and Iran. We analyzed clinical characteristics and in-hospital mortality stratified into age groups (<50, 50-70, >70 years). We applied cluster analyses to identify specific clinical phenotypes and their relationship with death. Results: The proportion of COVID-19 patients with stroke (1.8%, 95%CI 0.9-3.7%) and in-hospital mortality (34.4%, 95%CI 27.2-42.4%) were exceedingly high. Mortality was 67% lower in patients <50 years-old relative to those >70 years-old (OR 0.33, 95%CI 0.12-0.94, P=0.039). Large vessel occlusion was twice as frequent (46.9%) as previously reported and was high across all age groups, even in the absence of risk factors or comorbidities. A clinical phenotype characterized by older age, a higher burden of comorbidities, and severe COVID-19 respiratory symptoms, was associated with the highest in-hospital mortality (58.6%) and a 3x higher risk of death than the rest of the cohort (OR 3.52, 95%CI 1.53-8.09, P=0.003). Conclusions: Stroke is frequent among COVID-19 patients and has devastating consequences across all ages. The interplay of older age, comorbidities and severity of COVID-19 respiratory symptoms is associated with an extremely elevated mortality.

Comparison between the 30-day stroke in-hospital mortality rates for each year with the Canada average.

BackgroundSocial support can help to deal with the consequences of neurological conditions and promote functional independence and quality of life. Our aim was to evaluate the impact of neurological conditions on the use of support and health-care services in a population-based sample of community-dwelling adults with neurological conditions.MethodsData were from the Survey of Living with Neurological Conditions in Canada, which was derived from a representative sample of household residents. Formal and informal support received and out-of-pocket payments were assessed by personal interviews. Logistic regression was used to explore the association between support service utilization and six common neurological conditions (Stroke, Parkinson's disease, Alzheimer's disease/dementias, traumatic brain injury, spinal cord injury and multiple sclerosis) with stroke as the reference category.ResultsThe sample contained 2,410 respondents and equate to an estimated 459,770 when sample weights were used. A larger proportion of people within each of the neurological conditions received informal support than formal support (at least twice as much). Samples with the non-stroke conditions were more likely to receive formal assistance for personal (odds ratios 2.7 to 5.6; P < 0.05) and medical (odds ratios 2.4 to 4.4; P < 0.05) care compared to the stroke group. Also, the non-stroke conditions were more likely to receive informal assistance (odds ratios 2.7 to 17.9; P < 0.05) and less likely to make out-of-pocket payments for rehabilitation therapy (odds ratios 0.2 to 0.3; P < 0.05) than the stroke group. The Alzheimer’s disease/dementia group had the highest proportion who received formal and informal support services.ConclusionsOur findings suggest that Canadians with neurological conditions receive more informal assistance than formal assistance. Furthermore, it appears that stroke survivors receive less support services, while those with Alzheimer’s disease/dementia receive the most compared to other adult neurological conditions. Such data can help inform the development of support services in the community.

Snapshot img

Acute Ischemic Stroke Therapeutics Market Size 2024-2028

The acute ischemic stroke therapeutics market size is forecast to increase by USD 1.74 billion at a CAGR of 6.1% between 2023 and 2028.

The market is experiencing significant growth due to the rising prevalence of cardiovascular diseases and the integration of genomic and clinical data through translational bioinformatics in stroke management. The use of magnetic resonance imaging and data integration techniques in stroke diagnosis and treatment planning is also driving market growth. Unmet needs for anticoagulant reversal agents continue to be a major challenge In the market. In the digital health era, artificial intelligence (AI) and machine learning algorithms are increasingly being used to improve stroke diagnosis and treatment, particularly in remote areas where access to specialized care is limited. Telemedicine and digital platforms are also gaining popularity for stroke care, enabling faster response times and improved patient outcomes.
Key trends In the market include the development of thrombectomy devices for mechanical thrombectomy procedures and the use of statins for stroke prevention. Overall, the market is poised for growth, driven by technological advancements and unmet clinical needs.

What will be the Size of the Acute Ischemic Stroke Therapeutics Market During the Forecast Period?

Request Free Sample

The market encompasses a range of diagnostic and treatment modalities for managing ischemic stroke, a condition characterized by the sudden disruption of blood to the brain. Key diagnostic tools include computed tomography (CT), magnetic resonance imaging (MRI), carotid ultrasound, cerebral angiography, electrocardiography (ECG), echocardiography, and various imaging techniques.
Treatment options span from invasive procedures such as carotid endarterectomy, angioplasty, and endovascular mechanical thrombectomy, to pharmacological interventions like tissue plasminogen activator (tPA), anticoagulants, antiplatelets, antihypertensives, statins, and other drug classes. The market is driven by the growing prevalence of atherosclerosis plaques, which can lead to the formation of blood clots obstructing blood vessels.
The route of administration for these therapeutics varies, with both oral and parenteral options available. Distribution channels include hospital pharmacies and retail pharmacies. Overall, the market is expected to grow steadily due to the increasing incidence of acute ischemic stroke and the development of more effective and accessible treatment options.

How is this Acute Ischemic Stroke Therapeutics Industry segmented and which is the largest segment?

The acute ischemic stroke therapeutics industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD billion' for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.

Type

  Thrombolytics
  Anticoagulants
  Antiplatelets
  Antihypertensives
  Others


Distribution Channel

  Hospital pharmacies
  Retail pharmacies
  Online pharmacies


Geography

  North America

    Canada
    US


  Europe

    Germany
    UK


  Asia

    China


  Rest of World (ROW)

By Type Insights

The thrombolytics segment is estimated to witness significant growth during the forecast period. Thrombolytics, also known as clot-busting drugs, are essential therapeutics for treating acute ischemic stroke (AIS) caused by blood clots In the arteries supplying the brain. The primary goal is to restore blood flow and minimize brain cell damage. Notable neuroimaging techniques for diagnosing AIS include Computed Tomography (CT), MRI, carotid ultrasound, cerebral angiography, electrocardiography, and echocardiography. Thrombolytic agents, such as alteplase and tenecteplase, are administered intravenously to dissolve clots. Other treatments include Carotid Endarterectomy, Angioplasty, Endovascular Mechanical Thrombectomy, and various drug classes like anticoagulants, antiplatelets, antihypertensives, and statins. The aging population, high blood pressure, diabetes, and obesity contribute to the rising prevalence of AIS. Neuroimaging technologies continue to advance, and the Defense Health Agency supports ongoing research for improved AIS therapeutics. Thrombolytics are administered through hospital pharmacies, retail pharmacies, and online pharmacies.

Get a glance at the Acute Ischemic Stroke Therapeutics Industry report of share of various segments Request Free Sample

The Thrombolytics segment was valued at USD 2.61 billion in 2018 and showed a gradual increase during the forecast period.

Regional Analysis

North America is estimated to contribute 39% to the growth of the global market during the forecast period. Technavio's analysts have elaborately explained the regional trends and drivers that shape the ma

Comparison of rural hospital characteristics with and without CIHI data by year.